Safety and Efficacy of Monoamine Oxidase Inhibitors in Patients Using Psychoactive Substances
| Journal | CNS drugs |
| Study Type | Randomized Trial |
| Population | Human participants |
This item covers developments relevant to cannabis medicine and clinical practice. Clinicians monitoring evidence in this area should review the source material.
Monoamine oxidase inhibitors (MAOIs) remain an important option for patients with treatment-resistant depression (TRD) and other psychiatric conditions, despite potentially serious drug-drug interactions and associated dietary tyramine restrictions. However, they are rarely prescribed in patients with comorbid substance use disorders (SUDs) due to concerns about potential drug interactions and limited research in these populations. This narrative review investigates the use of MAOIs in patients who use psychoactive substances, exploring potential interactions while summarizing the relatively scant literature on using MAOIs as treatments for SUDs. It synthesizes data from 219 peer-reviewed publications investigating MAOI/psychoactive substance interactions or the use of MAOIs to treat SUDs or psychiatric conditions in patients with comorbid SUDs, including 20 randomized controlled trials, 18 non-randomized interventional trials, 32 observational studies/case series, 56 case reports, 85
“This is a development worth tracking. The clinical implications will become clearer as more evidence accumulates.”
💬 Join the Conversation
Want to apply this research to your care?
CED Clinic translates emerging research into individualized clinical care. Dr. Caplan has treated 30,000+ patients.
Book a consultation →Have a question about how this applies to your situation? Ask Dr. Caplan →
Want to discuss this topic with other patients and caregivers? Join the forum discussion →
Have thoughts on this? Share it:
FAQ
This study item was assembled from normalized source metadata and pipeline scoring.
